The effect of zofenopril on the cardiovascular system of spontaneously hypertensive rats treated with the ACE2 inhibitor MLN-4760

Table 2 General Characteristics of Experimental Animals

	SHR	SHR + MLN	SHR + ZOFE	SHR + MLN + ZOFE
n	20	20	20	20
ΔSBP (%)	5.87 ± 2.31	7.16 ± 2.83	-2.69 ± 2.04	6.65 ± 2.45
ΔBW (%)	6.05 ± 0.44	8.38 ± 0.45*	3.08 ± 0.8**	5 ± 0.71⁺⁺⁺
HW (g)	1.12 ± 0.04	1.21 ± 0.03	1.1 ± 0.01	1.04 ± 0.03⁺
HW/BW (mg/g)	3.72 ± 0.14	3.78 ± 0.09	3.46 ± 0.03	3.4 ± 0.09⁺
VF (g)	7.83 ± 0.33	8.99 ± 0.3*	8.17 ± 0.39	8.07 ± 0.19
VF/BW (mg/g)	25.1 ± 0.86	28.1 ± 0.93*	25.59 ± 1.07	26.24 ± 0.5
H₂S plasma (µM)	11.89 ± 2.41	22.7 ± 8.48***	14.27 ± 3.65	20.23 ± 6.74**
H₂S heart (nM/mg) – basal	826 ± 25.99	1020.67 ± 41.33***	1818.37 ± 127.84***	1079.76 ± 18.89***^§§§
H₂S heart (nM/mg) – activated	1062.67 ± 61.76	1534 ± 91.17**	2263.27 ± 223.52***	2020.24 ± 105.84***⁺⁺

Abbreviations: ΔSBP – the changes in systolic blood pressure, ΔBW – body weight gain, HW – heart weight, HW/BW – ratio of heart weight to body weight, VF – weight of visceral fat, VF/BW – ratio of visceral fat to body weight, n – number of rats. SHR – spontaneously hypertensive rats, SHR + MLN – spontaneously hypertensive rats treated by MLN-4760, SHR + ZOFE – spontaneously hypertensive rats treated by zofenopril, SHR + MLN + ZOFE – spontaneously hypertensive rats treated by MLN-4760 and zofenopril. The results are presented as the mean ± S.E.M., and differences between groups were analyzed by two-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. SHR,⁺ p < 0.05, ⁺⁺⁺p < 0.001 vs. SHR + MLN, ^§§§ p < 0.001vs. SHR + ZOFE

ISSN: 0717-6287